The Pro12Ala PPARγ2 gene missense mutation is associated with obesity and insulin resistance in Swedish middle-aged men

Diabetes/Metabolism Research and Reviews

Volumn 19, Issue 2, 2003, Pages 159-163

  Rosmond, Roland ^a,b   Chagnon, Monique ^b   Bouchard, Claude ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Pennington Biomedical Research Center   (United States)

Author keywords

Genes; Hormones; Insulin; Obesity; Polymorphism; PPAR 2

Indexed keywords

ALANINE; FAT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE; HYDROCORTISONE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROLINE; RESTRICTION ENDONUCLEASE; CELL RECEPTOR; TRANSCRIPTION FACTOR;

ADULT; AMINO ACID SUBSTITUTION; ANTHROPOMETRY; ARTICLE; BODY FAT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; GENE AMPLIFICATION; GENETIC ANALYSIS; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLUCOSE METABOLISM; HOMOZYGOSITY; HORMONE DETERMINATION; HUMAN; INSULIN METABOLISM; INSULIN RESISTANCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; OBESITY; ORAL GLUCOSE TOLERANCE TEST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; SALIVA LEVEL; SWEDEN; CAUCASIAN; DIABETES MELLITUS; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED;

DIABETES MELLITUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MIDDLE AGED; MUTATION, MISSENSE; OBESITY; POLYMORPHISM, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SWEDEN; TRANSCRIPTION FACTORS;

EID: 0037359269     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.371     Document Type: Article

References (33)

1. Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514.
2. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 421-424.
3. Lazar MA. Progress in cardiovascular biology: PPAR for the course. Nat Med 2001; 7(1): 23-24.
4. Elbrecht A, Chen Y, Cullinan CA, et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2. Biochem Biophys Res Commun 1996; 224: 431-437.
5. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000; 106: 467-472.
6. Beamer BA, Negri C, Yen CJ, et al. Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-γ (hPPARγ) gene. Biochem Biophys Res Commun 1997; 233: 756-759.
7. Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 1997; 272: 18 779-18 789.
8. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998; 339: 953-959.
9. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-287.
10. Yen CJ, Beamer BA, Negri C, et al. Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPARγ) gene in diabetic Caucasians: identification of a Pro12Ala PPARγ2 missense mutation. Biochem Biophys Res Commun 1997; 241: 270-274.
11. Koch M, Rett K, Maerker E, et al. The PPARγ2 amino acid polymorphism Pro12Ala is prevalent in offspring of Type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia 1999; 42: 758-762.
12. Valve R, Sivenius K, Miettinen R, et al. Two polymorphisms in the peroxisome proliferator-activated receptor-γ gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 1999; 84: 3708-3712.
13. Meirhaeghe A, Fajas L, Helbecque N, et al. Impact of the peroxisome proliferator activated receptor γ2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000; 24: 195-199.
14. Evans D, Mann WA, Heer J, et al. Variation in the gene for human peroxisome proliferator activated receptor γ (PPARγ) does not play a major role in the development of morbid obesity. Int J Obes Relat Metab Disord 2000; 24: 647-651.
15. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76-80.
16. Clement K, Hercberg S, Passinge B, et al. The Pro115Gln and Pro12Ala PPARγ gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord 2000; 24: 391-393.
17. Hasstedt SJ, Ren Q-F, Teng K, Elbein SC. Effect of the peroxisome proliferator-activated receptor-γ2 Pro12Ala variant on obesity, glucose homeostasis, and blood pressure in members of familial Type 2 diabetic kindreds. J Clin Endocrinol Metab 2001; 86: 536-541.
18. Rosmond R, Dallman MF, Björntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab 1998; 83: 1853-1859.
19. Rosmond R, Chagnon YC, Holm G, et al. Hypertension in obesity and the leptin receptor gene locus. J Clin Endocrinol Metab 2000; 85: 3126-3131.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
21. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
22. Ek J, Urhammer SA, Sorensen TI, Andersen T, Auwerx J, Pedersen O. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-γ2 (PPAR-γ2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 1999; 42: 892-895.
23. Björntorp P. Obesity. Lancet 1997; 350: 423-426.
24. Sjöström L, Lönn L, Chowdhury B, et al. The sagittal diameter is a valid marker of the visceral adipose tissue volume. In Progress in Obesity Research: 7, Angel A, Andersson H, Bouchard C, Lau L, Leiter L, Mendelson R (eds). John Libbey & Co: London, 1996; 309-319.
25. Rosmond R, Björntorp P. Endocrine and metabolic aberrations in men with abdominal obesity in relation to anxio-depressive infirmity. Metabolism 1998; 47: 1187-1193.
26. Rosmond R, Björntorp P. The interactions between hypothalamic-pituitary-adrenal axis activity, testosterone, insulin-like growth factor I and abdominal obesity with metabolism and blood pressure in men. Int J Obes Relat Metab Disord 1998; 22: 1184-1196.
27. Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest 2000; 106: 459-465.
28. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880-883.
29. Globerman H, Zauberman Y, Makarov T, et al. Analysis of the peroxisome proliferator activated receptor γ (PPARγ) gene in HAIRAN syndrome with obesity. Clin Endocrinol (Oxf) 2000; 52: 479-485.
30. Hamann A, Munzberg H, Buttron P, et al. Missense variants in the human peroxisome proliferator-activated receptor-γ2 gene in lean and obese subjects. Eur J Endocrinol 1999; 141: 90-92.
31. Ringel J, Engeli S, Distler A, Sharma AM. Pro12Ala missense mutation of the peroxisome proliferator activated receptor γ and diabetes mellitus. Biochem Biophys Res Commun 1999; 254: 450-453.
32. Celi FS, Shuldiner AR. The role of peroxisome proliferator-activated receptor gamma in diabetes and obesity. Curr Diabetes Rep 2002; 2: 179-185.
33. 3-adrenergic receptor and peroxisome proliferator-activated receptor-γ2 genes and obesity. Diabetes Care 2001; 24: 672-677.